Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma-Reference-Cited by-同舟云学术

Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma

Published:2024-04-26 Issue:9 Volume:67 Page:6987-7005
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Mizuguchi Mineyuki¹^ORCID,Nakagawa Yusuke²,Yokoyama Takeshi¹^ORCID,Okada Takuya²³^ORCID,Fujii Kanako⁴,Takahashi Kanoko⁵,Luan Nguyen Ngoc Thanh²,Nabeshima Yuko¹,Kanamitsu Kayoko⁶,Nakagawa Shinsaku⁷,Yamakawa Shiori⁸,Ueda Mitsuharu⁸,Ando Yukio⁹,Toyooka Naoki²³^ORCID

Affiliation:

1. Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan

2. Graduate School of Innovative Life Science, University of Toyama, Toyama 930-8555, Japan

3. Faculty of Engineering, University of Toyama, Toyama 930-8555, Japan

4. Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan

5. Graduate School of Pharma-Medical Sciences, University of Toyama, Toyama 930-8555, Japan

6. Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo 113-0033, Japan

7. Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan

8. Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan

9. Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo 859-3298, Japan

Funder

Tamura Science and Technology Foundation

Japan Agency for Medical Research and Development

Japan Science and Technology Agency

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02286

Reference63 articles.

1. Guideline of transthyretin-related hereditary amyloidosis for clinicians

2. Recent advances in transthyretin amyloidosis therapy

3. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments

4. Ocular Involvement in Hereditary Amyloidosis